Cite
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
MLA
Luo, Hong-Yu, et al. “Association between the NEP Rs701109 Polymorphism and the Clinical Efficacy and Safety of Sacubitril/Valsartan in Chinese Patients with Heart Failure.” European Journal of Clinical Pharmacology, vol. 79, no. 5, May 2023, pp. 663–70. EBSCOhost, https://doi.org/10.1007/s00228-023-03484-6.
APA
Luo, H.-Y., Gao, L.-C., Long, H.-Z., Zhou, Z.-W., Xu, S.-G., Li, F.-J., Li, H.-L., Cheng, Y., Li, C.-X., Peng, X.-Y., Li, L., Chen, R., & Deng, P. (2023). Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure. European Journal of Clinical Pharmacology, 79(5), 663–670. https://doi.org/10.1007/s00228-023-03484-6
Chicago
Luo, Hong-Yu, Li-Chen Gao, Hui-Zhi Long, Zi-Wei Zhou, Shuo-Guo Xu, Feng-Jiao Li, Hong-Li Li, et al. 2023. “Association between the NEP Rs701109 Polymorphism and the Clinical Efficacy and Safety of Sacubitril/Valsartan in Chinese Patients with Heart Failure.” European Journal of Clinical Pharmacology 79 (5): 663–70. doi:10.1007/s00228-023-03484-6.